hydroxyurea


Also found in: Medical, Encyclopedia, Wikipedia.

hy·drox·y·u·re·a

 (hī-drŏk′sē-yo͝o-rē′ə)
n.
An antineoplastic drug, CH4N2O2, that suppresses the production of blood cell precursors in the bone marrow and is used in the treatment of certain leukemias, carcinomas, and sickle cell anemia.

hydroxyurea

(haɪˌdrɒksɪjʊˈrɪə)
n
(Medicine) a drug which prevents the development of tumours and is used in the treatment of certain types of cancer as well as in the treatment of sickle-cell disease and AIDS
Translations

hydroxyurea

n hidroxiurea, hidroxicarbamida (INN)
Mentioned in ?
References in periodicals archive ?
Tenders are invited for Hydroxyurea usp, gmp grade material
CONTI-PV is an open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of Ropeginterferon alfa-2b versus hydroxyurea or best available treatment in patients with PV who previously participated in the pivotal phase III PROUD-PV study.
Another treatment option is the daily administration of a drug called hydroxyurea.
Hydroxyurea is a chemotherapeutic agent that increases the production of fetal hemoglobin and decreases SCD-related complications.
22 patients were on hydroxyurea (HU) before pregnancy, but stopped after confirmation of pregnancy.
Previously, the only drug approved for treating sickle cell disorder was hydroxyurea, which the FDA green lighted in 1998.
This planned Phase 3 clinical trial will enroll patients with essential thrombocythemia who have either failed or are intolerant to hydroxyurea, and will compare GALE-401 to the best available therapy (BAT) that will include a sizable subpopulation of patients treated with anagrelide immediate release, added the company.
Hydroxyurea (also referred to as hydroxycarbamide) is a cytotoxic, antimetabolic, and antineoplastic agent with a remarkable breadth of therapeutic activity for a wide variety of human diseases.
He also highlighted several approaches to aid sickle cell sufferers including vaccinations, regular hospital visits and taking hydroxyurea, a chemotherapy drug with anti-retroviral properties.
In 2014, indications for ruxolitinib were expanded to include treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
Ruxolitinib (Jakafi) is a first-in-class JAK1/JAK2 inhibitor approved by the US Food and Drug Administration for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
The neurologist was consulted and along with the haematologist, the data was reviewed for this rare entity and she was started on 10 mg/kg hydroxyurea along with anti-epileptics and anti-platelets.